3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Nasopharyngeal Carcinoma
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Cancer Metastatic
1
Nasopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Renal Cell Carcinoma (RCC)
1
Advanced Malignant Solid Tumors
1
Advanced Lung Cancer
1
Advanced Breast Cancer
1
Interventions
Carboplatin
13
pembrolizumab
12
Specimen Handling
9
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Capecitabine
5
Biopsy
5
Nivolumab
4
Cyclophosphamide
4
sacituzumab govitecan
3
Gemcitabine
3
Fulvestrant
3
olaparib
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Taxes
2
Letrozole
2
Epirubicin
2
Docetaxel
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
toripalimab
1
sintilimab
1
pyrotinib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
toripalimab
×
30 days
×
Clear all
NCT06618014
2026-05-15
NeoTOP
Sun Yat-sen University
Phase 2
Active not recruiting
51 enrolled